{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:30:12Z","timestamp":1792290612867,"version":"4.4.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Thalidomide, once discovered and used to treat pregnancy sickness, fell out of favor with teratogenicity scandals, and then re-entered the public eye with its amazing efficacy against leprosy and multiple myeloma, and its anti-tumor and anti-inflammatory effects were gradually discovered. In recent years, thalidomide has also begun to gain prominence for its role in digestive disorders, particularly for its anti-angiogenic effects, which are effective in the treatment of dysplastic gastrointestinal hemorrhage. The therapeutic effects of thalidomide in other digestive disorders, including radiation proctitis, inflammatory bowel disease, and malignant tumors of the digestive tract, such as liver, colorectal, gastric, esophageal, and pancreatic cancers, have been proposed in several clinical trials and case reports. Due to its potential adverse effects and controversial clinical utility, it has not been put into clinical use for digestive diseases in large numbers, but its unique therapeutic effects still warrant further study, so this paper analyses and summarizes the use, mechanism of action, and potential therapeutic uses of thalidomide in digestive diseases.<\/jats:p>","DOI":"10.3389\/fonc.2025.1543757","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:13:30Z","timestamp":1748492010000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["A review of thalidomide and digestive system related diseases"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhao","family":"Xi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zou","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Shasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2174\/09298673113209990198","article-title":"Thalidomide-a notorious sedative to a wonder anticancer drug","volume":"20","author":"Zhou","year":"2013","journal-title":"Curr Med Chem"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/0753-3322(89)90089-9","article-title":"Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation","volume":"43","author":"McCarthy","year":"1989","journal-title":"BioMed Pharmacother"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200304060-00002","article-title":"Thalidomide in cutaneous lupus erythematosus","volume":"4","author":"Pelle","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2024.05.001","article-title":"Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy","volume":"30","author":"Colley","year":"2024","journal-title":"Trends Mol Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-010-0619-9","article-title":"Teratogenic effects of thalidomide: molecular mechanisms","volume":"68","author":"Ito","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1039\/D2CS00116K","article-title":"Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders","volume":"51","author":"Yamamoto","year":"2022","journal-title":"Chem Soc Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1743467","article-title":"Systemic antiangiogenic therapies for bleeding in hereditary hemorrhagic telangiectasia: A practical, evidence-based guide for clinicians","volume":"48","author":"Al-Samkari","year":"2022","journal-title":"Semin Thromb Hemost"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021765","article-title":"How I treat bleeding in hereditary hemorrhagic telangiectasia","volume":"144","author":"Al-Samkari","year":"2024","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312749","article-title":"Pomalidomide for epistaxis in hereditary hemorrhagic telangiectasia","volume":"391","author":"Al-Samkari","year":"2024","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443050-00004","article-title":"Clinical pharmacokinetics of thalidomide","volume":"43","author":"Teo","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/385303b0","article-title":"Thalidomide\u2019s chirality","volume":"385","author":"Wnendt","year":"1997","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0901505106","article-title":"Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation","volume":"106","author":"Therapontos","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/152308604771978291","article-title":"A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-kappaB pathway","volume":"6","author":"Hansen","year":"2004","journal-title":"Antioxid Redox Signal"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303706","article-title":"Thalidomide for recurrent bleeding due to small-intestinal angiodysplasia","volume":"389","author":"Chen","year":"2023","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.029710","article-title":"Thalidomide for treatment of severe intestinal bleeding","volume":"53","author":"Bauditz","year":"2004","journal-title":"Gut"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00222-7","article-title":"Thalidomide for hereditary haemorrhagic telangiectasia","volume":"2","author":"Franchini","year":"2015","journal-title":"Lancet Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-944829","article-title":"Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide","volume":"38","author":"Bauditz","year":"2006","journal-title":"Endoscopy"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1053\/j.gastro.2011.07.018","article-title":"Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation","volume":"141","author":"Ge","year":"2011","journal-title":"Gastroenterology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.3390\/jcm13185404","article-title":"The role of thalidomide and its analogs in the treatment of hereditary hemorrhagic telangiectasia: A systematic review","volume":"13","author":"Ugur","year":"2024","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/apt.2015.41.issue-5","article-title":"Long-term outcomes of thalidomide in refractory Crohn\u2019s disease","volume":"41","author":"Gerich","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1097\/00042737-200605000-00016","article-title":"Refractory bleeding from portal hypertensive gastropathy: a further novel role for thalidomide therapy","volume":"18","author":"Karajeh","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"E384","DOI":"10.1055\/s-0034-1377369","article-title":"Evidence that thalidomide is effective in recurrent bleeding from watermelon stomach associated with liver cirrhosis","author":"Moser","year":"2014","journal-title":"Endoscopy"},{"key":"B25","article-title":"Upper gastrointestinal bleeding in patients with chronic renal failure: role of vascular ectasia","volume":"91","author":"Chalasani","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.46","article-title":"Radiation enteropathy\u2013pathogenesis, treatment and prevention","volume":"11","author":"Hauer-Jensen","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e2401634","DOI":"10.1002\/advs.202401634","article-title":"T Cell-Derived Apoptotic Extracellular Vesicles Hydrolyze cGAMP to Alleviate Radiation Enteritis via Surface Enzyme ENPP1","volume":"11","author":"Zhou","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3971\/j.issn.1000-8578.2017.05.008","article-title":"Clinical observation on prevention and treatment effect of thalidomide on acute radiation proctitis","volume":"44","author":"Jiao","year":"2017","journal-title":"Cancer Res Prev Treat"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.2008.i107","article-title":"Immunomodulation by thalidomide and thalidomide analogues","author":"Corral","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(99)00250-4","article-title":"Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production","volume":"9","author":"Muller","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"key":"B31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/gut.50.2.196","article-title":"Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn\u2019s disease","volume":"50","author":"Bauditz","year":"2002","journal-title":"Gut"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03339-X","article-title":"Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn\u2019s disease","volume":"353","author":"Schreiber","year":"1999","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70276-3","article-title":"Thalidomide therapy for patients with refractory Crohn\u2019s disease: an open-label trial","volume":"117","author":"Ehrenpreis","year":"1999","journal-title":"Gastroenterology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70277-5","article-title":"An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn\u2019s disease","volume":"117","author":"Vasiliauskas","year":"1999","journal-title":"Gastroenterology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.280777","article-title":"Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial","volume":"310","author":"Lazzerini","year":"2013","journal-title":"Jama"},{"key":"B36","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.cgh.2015.10.034","article-title":"Long-term outcomes of thalidomide therapy for adults with refractory crohn\u2019s disease","volume":"14","author":"Simon","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"goac032","DOI":"10.1093\/gastro\/goac032","article-title":"Efficacy and safety of low-dose thalidomide combined with mesalazine in the treatment of refractory ulcerative colitis in adults","volume":"10","author":"Chen","year":"2022","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/apt.2015.41.issue-11","article-title":"Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease","volume":"41","author":"Yang","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"goac052","DOI":"10.1093\/gastro\/goac052","article-title":"The efficacy and safety of thalidomide in the treatment of refractory Crohn\u2019s disease in adults: a double-center, double-blind, randomized-controlled trial","volume":"10","author":"Peng","year":"2022","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i24.3855","article-title":"Comparison and development of machine learning for thalidomide-induced peripheral neuropathy prediction of refractory Crohn\u2019s disease in Chinese population","volume":"29","author":"Mao","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(94)80092-8","article-title":"Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study","volume":"21","author":"McCormick","year":"1994","journal-title":"J Hepatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464200-00001","article-title":"Options for treatment of primary biliary cirrhosis","volume":"64","author":"Oo","year":"2004","journal-title":"Drugs"},{"key":"B43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117457","article-title":"Thalidomide for treatment of multiple myeloma: 10 years later","volume":"111","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMc060958","article-title":"Thalidomide for multiple myeloma","volume":"354","author":"Folkman","year":"2006","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.034","article-title":"Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial","volume":"20","author":"Hwu","year":"2002","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2007-060","article-title":"Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme","volume":"10","author":"Puduvalli","year":"2008","journal-title":"Neuro Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/annonc\/mdi002","article-title":"Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens","volume":"16","author":"Amato","year":"2005","journal-title":"Ann Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.536","article-title":"Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma","volume":"21","author":"Hernberg","year":"2003","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v103:4","article-title":"Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial","volume":"103","author":"Patt","year":"2005","journal-title":"Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i43.6955","article-title":"Efficacy and safety of thalidomide in patients with hepatocellular carcinoma","volume":"12","author":"Chiou","year":"2006","journal-title":"World J Gastroenterol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/apt.2017.46.issue-8","article-title":"Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy","volume":"46","author":"Shao","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"B54","article-title":"A randomised controlled phase II trial of the combination of XELOX with thalidomide for the first-line treatment of metastatic colorectal cancer","volume":"9","author":"Lv","year":"2012","journal-title":"Cancer Biol Med"},{"key":"B55","article-title":"Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts","volume":"43","author":"Kinuya","year":"2002","journal-title":"J Nucl Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2024.04.108","article-title":"Effect of CAPEOX combined with thalidomide in the treatment of elderly patients with colon cancer: A single-center report","volume":"47","author":"Zhong","year":"2024","journal-title":"Asian J Surg"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02728","article-title":"Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study","volume":"42","author":"Antoniotti","year":"2024","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02586-1","article-title":"Effect of thalidomide on gastrointestinal toxic effects of irinotecan","volume":"356","author":"Govindarajan","year":"2000","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.047563","article-title":"Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial","volume":"54","author":"Gordon","year":"2005","journal-title":"Gut"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2024.01.009","article-title":"Addressing cancer anorexia-cachexia in older patients: Potential therapeutic strategies and molecular pathways","volume":"43","author":"Ispoglou","year":"2024","journal-title":"Clin Nutr"},{"key":"B61","first-page":"Cd008664","article-title":"Thalidomide for managing cancer cachexia","volume":"2012","author":"Reid","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01457.x","article-title":"Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass","volume":"17","author":"Khan","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/jop.2013.42.issue-5","article-title":"Thalidomide: features and potential significance in oral precancerous conditions and oral cancer","volume":"42","author":"Jin","year":"2013","journal-title":"J  Pathol Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112144-20220111-00012","article-title":"Diagnosis and management of recurrent aphthous ulcer","volume":"57","author":"Shi","year":"2022","journal-title":"Zhonghua Kou Qiang Yi Xue Za Zhi"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112144-20211115-00505","article-title":"Guideline for the diagnosis and treatment of oral lichen planus (revision)","volume":"57","year":"2022","journal-title":"Zhonghua Kou Qiang Yi Xue Za Zhi"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16464","article-title":"European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology","volume":"34","author":"Ioannides","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B67","first-page":"74","article-title":"Guideline for the diagnosis and treatment of recurrent aphthous stomatitis for dental practitioners","volume":"7","author":"Tarakji","year":"2015","journal-title":"J Int  Health"},{"key":"B68","article-title":"Recurrent aphthous stomatitis (RAS): guideline for differential diagnosis and management","volume":"23","author":"Milia","year":"2022","journal-title":"Eur J Paediatr Dent"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/jop.12960","article-title":"The efficacy and safety of thalidomide on the recurrence interval of continuous recurrent aphthous ulceration: A randomized controlled clinical trial","volume":"49","author":"Zeng","year":"2020","journal-title":"J  Pathol Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e15500","DOI":"10.1111\/dth.15500","article-title":"Recurrent aphthous stomatitis: A comprehensive review and recommendations on therapeutic options","volume":"35","author":"Lau","year":"2022","journal-title":"Dermatol Ther"},{"key":"B71","article-title":"Adverse drug reactions associated with thalidomide treatment for oral mucosal diseases: a report of 44 cases","volume":"31","author":"Xiaojuan","year":"2024","journal-title":"Chin J Primary Med Pharmacy"},{"key":"B72","article-title":"Analysis of 1221 cases on adverse drug reaction\/event induced by thalidomide","volume":"25","author":"Ge","year":"2017","journal-title":"Pharmaceutical Clin Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1543757\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T13:11:35Z","timestamp":1750338695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1543757\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":72,"alternative-id":["10.3389\/fonc.2025.1543757"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1543757","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"article-number":"1543757"}}